Unlike PetMed, Phibro has said it is facing demand and supply disruptions because of COVID-19. It also has been hurt by reduced demand because of the effects of the African swine fever currently hitting Asia. Still, the news in the company's third-quarter report wasn't a disaster. Net sales were $211 million, an increase of 2% over the same quarter in 2019. Net income, however, was $14 million, a 9% drop, and earnings per share fell four cents to $0.33.